Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of tumor stem cell-specific dendritic cell therapy for hepatocellular carcinoma...The data were presented at the American Society for Gene and Cell Therapy annual meeting in Salt Lake City
Sangamo BioSciences Inc., of Richmond, Calif., said data demonstrating the successful application of its in vivo protein replacement platform (IVPRP) to produce therapeutically relevant levels of Factor VIII in a mouse model were presented at the annual meeting of the American Society of Gene and Cell Therapy
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of human adipose-derived mesenchymal progenitor cells therapy for knee osteoarthritis
The data were presented by researchers from Nuvo and the Fraunhofer Institute for Cell Therapy and Immunology IZI at the annual meeting of the American Association of Immunologists in Honolulu
Sangamo BioSciences Inc., of Richmond, Calif., said it presented new clinical data, which demonstrated that SB-728-T treatment resulted in a reduction in the HIV reservoir in HIV-infected subjects, at the 16th Annual Meeting of the American Society of Gene and Cell Therapy in Salt Lake City
RepliCel Life Sciences Inc., of Vancouver, British Columbia, said it started clinical development of an autologous cell therapy for the treatment of a variety of chronic tendon injuries, including Achilles, patellar and elbow
Bone Therapeutics SA, of Gosselies, Belgium, said its partner, the Rheumatology Department of Erasme University Hospital in Brussels, Belgium, initiated a Phase IIa trial testing lead bone cell therapy product, Preob, for the treatment of severe osteoporosis patients who do not respond to pharmacological treatment...Preob is an autologous osteoblastic cell therapy currently in two pivotal Phase III trials to treat osteonecrosis and nonunion fractures
BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis
Neuralstem Inc., of Rockville, Md., said it has received FDA approval to start a Phase I trial of lead cell therapy candidate NSI-566 in chronic spinal cord injury patients...The first 12 patients, of a planned 18, have been administered SB632, with no safety concerns attributed to the cell therapy
Azficel-T, an autologous cell therapy, previously gained approval as Laviv for improving the appearance of moderate to severe nasolabial folds or wrinkles in adults
The study is being funded by the National Heart, Lung, and Blood Institute and managed by the Cardiovascular Cell Therapy Research Network (CCTRN), which is also responsible for enrolling patients
Fate Therapeutics Inc., of San Diego, initiated a Phase II study of its hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancy
The Belgian Federal Agency for Medicines and Health Products gave authorization to Cardio3 BioSciences, of Mont-Saint-Guibert, Belgium, to begin a Phase III trial of C3BS-CQR-1, an autologous stem cell therapy, for congestive heart failure
Cryopraxis Cryobiology Ltd., of Rio de Janeiro, Brazil, and affiliate CellPraxis, of São Paulo, Brazil, plan to begin patient recruitment for the Brazilian arm of a Phase III refractory angina cell therapy trial by the end of 2012 or early 2013
One study will investigate Cytori's cell therapy as a treatment for ischemic heart failure and the other for cirrhosis of the liver...In each study, patients will receive an injection of Cytori's cell therapy, which consists of the patient's own adipose-derived stem and regenerative cells (ADRCs) processed using Cytori's Celution system
Cytori Therapeutics Inc., of San Diego, said an investigator-sponsored trial has been cleared to start in France to study the company's cell therapy as a potential treatment for limited and diffuse cutaneous systemic sclerosis
Cytori Therapeutics Inc., of San Diego, began a Phase I/II trial (ATHENA) of its cell therapy for refractory heart failure resulting from myocardial ischemia...who will be randomized to cell therapy or inactive placebo injection
NeoStem Inc., of New York, said an article published by the International Scholarly Research Network provided further evidence that cell therapy AMR-001, the company's lead candidate through its Amorcyte subsidiary, appeared to be capable of preserving heart muscle function following a large myocardial infarction
Cellular Biomedicine Group Inc., of Palo Alto, Calif., achieved 50 percent enrollment of the total projected enrollment required for its Phase I trial to evaluate the safety and preliminary efficacy of tumor stem cell-specific dendritic cell therapy for hepatocellular carcinoma...The data were presented at the American Society for Gene and Cell Therapy annual meeting in Salt Lake City